Promiximab-duocarmycin, a new CD56 antibody-drug conjugates, is highly efficacious in small cell lung cancer xenograft models

Small cell lung cancer (SCLC) is of a highly invasive and metastatic lung cancer subtype and there had not been effective targeted therapies. CD56, a cell surface marker highly expressed on most SCLC, is a promising therapeutic target for treatment of this aggressive cancer. In this study, we genera...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Yu, Lin, Lu, Ying, Yao, Yuqin, Liu, Yu, Wang, Yuxi, Lai, Qinhuai, Zhang, Ruirui, Li, Wenting, Wang, Ruixue, Fu, Yuyin, Tao, Yiran, Yi, Shuli, Gou, Lantu, Chen, Ligong, Yang, Jinliang
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5797043/
https://ncbi.nlm.nih.gov/pubmed/29435172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.23708
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados